(NewsDirect)
Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactivefollowing the Therapeutic Goods Administration (TGA)’s decision todown-schedule MDMA and psilocybin to Schedule 8 'ControlledMedicines' from July 2023. Winlo says the clinical-stage biotech,backed by Australian billionaire Andrew Forrest, is well-positioned toaccelerate patient access to MDMA-assisted therapies. ReschedulingMDMA opens a pathway to registration and reimbursement for MDMA andits analogues.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.